Twist Bioscience Reports Record Revenue and Improved Margins in Q3 FY2024

Details

The company's gross margin improved to 43.3%, up from 34.4% in the third quarter of fiscal 2023. Additionally, Twist Bioscience updated its full-year revenue guidance to approximately $310 million to $311 million, with an expected gross margin at the high end of the range at approximately 42.0%. The company also highlighted its strong growth in NGS and SynBio products, as well as the launch of new products including Express Antibodies and Multiplexed Gene Fragments.

Items reported

Exhibits (1)

About Twist Bioscience Corporation

Twist Bioscience Corporation is a synthetic biology company that develops and sells DNA-based products for research and commercial applications. Twist Bioscience Corporation’s portfolio includes synthetic genes, gene fragments, oligonucleotide pools, and antibody libraries used in therapeutic discovery, diagnostics, agriculture, industrial biotechnology, and academic research. The company also supports advanced workflows such as targeted next-generation sequencing, CRISPR gene editing, mutagenesis, and DNA data storage. Its proprietary semiconductor-based DNA synthesis platform is designed to produce high-quality synthetic DNA at scale, helping customers move from design to experimentation more efficiently. Twist Bioscience Corporation serves biotechnology, pharmaceutical, industrial, and academic customers across multiple regions, making it an important supplier in the life sciences tools and synthetic biology market.